Key practical implications include the following: 1) Post-MS patients may require prolonged treatment or higher liraglutide doses to match non-surgical outcomes, consistent with 56-week data showing 3.0 mg’s superiority over 1.8 mg (30); and 2) Dual incretin agonists (e.g., GLP-1/GIP co-agonists) may circumvent reduced GLP-1R sensitivity, as evidenced by recent trials (31). This evidence concerns the gene GLP1R and myeloid sarcoma.